The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 31, 2021
Filed:
May. 11, 2016
Applicant:
4p-pharma, Lille, FR;
Inventors:
Yoram Sela, Raanana, IL;
Itschak Lamensdorf, Modiin, IL;
Assignee:
4P-Pharma, Lille, FR;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/16 (2006.01); A61K 31/485 (2006.01); A61K 31/4458 (2006.01); A61K 9/28 (2006.01); A61K 9/50 (2006.01); A61K 9/00 (2006.01); A61K 9/48 (2006.01); A61P 25/00 (2006.01); C07D 221/18 (2006.01); C07D 211/34 (2006.01); A61K 45/06 (2006.01); A61K 31/137 (2006.01); A61K 31/473 (2006.01); C07D 401/06 (2006.01); A61K 36/74 (2006.01); A61K 31/4535 (2006.01); C07D 409/06 (2006.01); A61K 31/445 (2006.01); A61K 31/165 (2006.01); C07D 489/02 (2006.01); A61K 31/454 (2006.01); A61K 31/4468 (2006.01);
U.S. Cl.
CPC ...
A61K 9/1676 (2013.01); A61K 9/0002 (2013.01); A61K 9/0053 (2013.01); A61K 9/1623 (2013.01); A61K 9/2886 (2013.01); A61K 9/4808 (2013.01); A61K 9/4858 (2013.01); A61K 9/5078 (2013.01); A61K 9/5084 (2013.01); A61K 31/137 (2013.01); A61K 31/165 (2013.01); A61K 31/445 (2013.01); A61K 31/4458 (2013.01); A61K 31/4468 (2013.01); A61K 31/454 (2013.01); A61K 31/4535 (2013.01); A61K 31/473 (2013.01); A61K 31/485 (2013.01); A61K 36/74 (2013.01); A61K 45/06 (2013.01); A61P 25/00 (2018.01); C07D 211/34 (2013.01); C07D 221/18 (2013.01); C07D 401/06 (2013.01); C07D 409/06 (2013.01); C07D 489/02 (2013.01); A61K 2300/00 (2013.01);
Abstract
The present invention provides an abuse deterrent oral fixed-dose composition, comprising a stimulant or opioid and an abuse deterrent active, wherein the abuse deterrent active is configured to be bioavailable only when the composition is crushed, ground or dissolved.